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The median survival time for all patients was 7.4 months with a 1-year 
survival of 28%. Median survival for arm A was 9.4 months, for arm B 
6.8 months. (p=0.6 log rank test). 
Conclusions: the regimen with Carboplatin on day 8 is associated 
with less grade 3-4 neutropenia and thrombocytopenia without loss of 
response rate and is to be preferred.
Table 1.
 overall arm A arm B
Number of patients 69 34 35
Gender 
male 52 25 27
female 17 9 8
Age 
median 61 61 61
range 39-77 41-77 39-74
ECOG Performance 
O 11 6 5
1 58 28 30
Stage of disease    
IIIB 13 6 7
IV 56 28 28
Histology 
squamous 14 8 6
adenocarcinoma 33 17 16
other 22 9 13
Table 2.
Toxicity Arm A Arm B p-value
platelets/ANC gr 3-4 26 (79%) 17 (5O%) O.O14
platelets/ANC gr 4 10 (3O%) 1 (3%) O.OO3
platelets gr 3-4 22 (66.67%) 9 (26.47%) O.OO1
ANC gr 3-4 18 (54.55%) 12 (35.29%) O.113
Response 21% (95% CI, 8-41%) 20% (95% CI, 8-39%) O.89
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Background: A few prospective studies concerning diagnosis and 
treatment of large cell neuroendocrine lung cancer have been pub-
lished, as this tumor seems relatively rare. After the new World Health 
Organisation classiﬁcation of lung tumors in 1999, a result of previous 
or retrospective studies based on the old classiﬁcation seems unexploit-
able. So the GFPC started a prospective study, to establish the efﬁcien-
cy of Cisplatinum /Etoposide chemotherapy patients with LCNE lung 
cancer, diagnosed on the basis of the morphological Travis’s criteria 
and immunohistochemistry. A total of 50 patients was planned.
Methods: Patients with stage IV and stage III B (with neoplasic pleural 
effusion) were selected; treatment is three cycles of Cisplatinum 80mg/
m2 d1 / Etoposide 100mg/m2 d1d2d3 and two more cycles in case of 
Objective Response or Stable disease.
The primary objective was the efﬁciency of this chemotherapy, in 
term of objective response and survival rate. The secondary objectives 
were the improvement of the pathologic diagnosis, with validation of 
the paranuclear granular expression of a large spectrum cytokeratin 
(antibodies). 
Results: In this protocol, 27 patients were included since May 2004. 
The slides of 21 cases were reviewed by a panel of pathologists, mem-
bers of GFPC. Diagnoses were controlled on the basis of the Travis’s 
criteria. 14 cases were conﬁrmed as LCNEC. 4 were excluded on the 
basis of the nuclear criteria or cell size, which made them classiﬁed as 
small-cell carcinomas (SCC). One was excluded, because immunohis-
tochemistry was not available. Two other patients were excluded be-
cause of the misinterpretation of the pathologic report by the clinicians. 
One had been concluded as a SCC, the other as a large cell carcinoma.
After treatment, thirteen patients are assessable for response, a patient 
died eight days after inclusion in the protocol: the chemotherapy was 
well tolerated in eleven cases, the main toxicity was haematological, 
but gastric and renal toxicity appeared in two cases after the ﬁrst cycles 
of chemotherapy and this patients had to used the other treatment . 
In the other cases, after 3 cycles of chemotherapy there was no Com-
plete Response, six Partial Response, three Stable Disease and four 
Progressions and after 5 cycles only four Partial Response, two Stable 
Disease and six Progressions. 
At mars 2007, three patients are alive and eleven patients died. The 
median survival time was 33 weeks.
Conclusion: With twenty seven patients included in this protocol since 
three years and only fourteen patients with LCNEC, it appears that this 
cancer is rarely diagnosed. The main pathological confusion is between 
small-cell and large cell-carcinoma. At last, this chemotherapy seems 
to give good results after three ﬁrst cycles but the effectiveness with 
ﬁve cycles does not seem better than other combinations containing 
platinum. Perhaps is it necessary to propose after three cycles of induc-
tion with cisplatine - etoposide an early modiﬁcation of chemotherapy 
in this rare shape of bronchopulmonary cancer ?
Results will be updated at the meeting
